Mucinex® for Treatment of Filamentary Keratitis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-09-30

Study Completion Date

2018-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It is a pilot study aimed to determine if oral Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Mucin Levels in Dry Eye and Normal Populations

NCT05911555

Dry Eye

COMPLETED

Clinical Trial to Evaluate the Chronic Efficacy of OC-01 Nasal Spray on Signs of Dry Eye Disease (The MYSTIC Study)

NCT03873246

Dry Eye Disease

COMPLETED PHASE2

Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

NCT01189032

Dry Eye

COMPLETED PHASE2

A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome

NCT02139033

Keratoconjunctivitis Sicca

COMPLETED PHASE4

Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

NCT03636061

Dry Eye Disease

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is aimed to determine if oral administration of Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis. Subjects will be instructed to take 600 mg tablets of extended release Mucinex® twice a day (total dose is 1.2 g/day) for 4 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Filamentary Keratitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mucinex

600 mg of Mucinex 2 times a day.

Group Type OTHER

Mucinex®

Intervention Type DRUG

Mucinex®

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mucinex®

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Guaifenesin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with filamentary keratitis
* 18 years and older

Exclusion Criteria

* Active ocular surface infection of any type
* Recent ocular surgery (\<30 days) history of nephrolithiasis as Mucinex® has been associated in rare cases of development of kidney stones
* Schirmer's test\<3mm
* History of hypersensitivity to Mucinex®
* Concurrent eye disease requiring immediate initiation of a new treatment (e.g. topical steroids) restriction for water intake can exacerbate the risk of nephrolithiasis.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No